Biodexa Pharmaceuticals (BDRX) Total Debt (2013 - 2025)

Biodexa Pharmaceuticals (BDRX) has 13 years of Total Debt data on file, last reported at $16.6 million in Q4 2025.

• For the quarter ending Q4 2025, Total Debt rose 37.58% year-over-year to $16.6 million; the trailing twelve-month figure through Dec 2025 stood at $16.6 million (up 37.58% YoY), and the FY2025 full-year result was $16.5 million, up 36.37% from the prior year.
• Total Debt rose to $16.6 million in Q4 2025, from $668356.9 in the prior quarter.
• In the past five years, Total Debt ranged from a high of $16.6 million in Q4 2025 to a low of $262541.9 in Q2 2024.
• A 5-year average of $8.2 million and a median of $9.4 million in 2021 frame the typical range for Total Debt.
• Across the five-year window, Total Debt plunged 95.65% in 2023 and surged 154.57% in 2025, its largest moves.
• Tracing BDRX's Total Debt over 5 years: stood at $16.1 million in 2021, then plunged by 64.57% to $5.7 million in 2022, then jumped by 57.1% to $8.9 million in 2023, then jumped by 35.3% to $12.1 million in 2024, then surged by 37.58% to $16.6 million in 2025.
• Business Quant data shows BDRX's Total Debt at $16.6 million in Q4 2025, $668356.9 in Q2 2025, and $12.1 million in Q4 2024.